Prometheus Research appoints vp of sales
Prometheus Research, a US provider of database software for biomedical researchers and industry, has named Peter Harker as its new vice president of sales.
Harker takes responsibility for developing and managing sales for the company's Research Informatics biomedical software services and new HTSQL database software for industry.
Prior to joining Prometheus, Harker held a variety of sales roles, most recently as managing director for BondDesk, a provider of software and services for fixed income trading.
You may also like
Finance
Agarose Bead Technologies marks 25 years with $10m global expansion plan
The Spanish agarose resin specialist will expand into the US and India, invest in scalable bioprocessing technologies and enhance sustainability across its European facilities to meet growing demand for advanced therapy purification
Packaging
Sharp Services invests $100m to expand global sterile and packaging capacity across US and Europe
The investment will boost sterile fill/finish, injectable packaging and oral solid dose capacity across Sharp's US and European sites, strengthening its clinical and commercial manufacturing network to meet growing pharmaceutical demand
Finance
MilliporeSigma to acquire JSR Life Sciences’ chromatography business, boosting Protein A purification capabilities
The acquisition expands MilliporeSigma’s downstream bioprocessing portfolio with JSR’s Amsphere Protein A resin technology, enhancing efficiency and reliability in monoclonal antibody and therapeutic protein production
Finance
Wilmington PharmaTech secures further funding for its expansion from Curewell Capital
The CDMO's partnership with Curewell will provide significant growth capital to expand WPT’s manufacturing capacity and further scale its end-to-end capabilities in producing a full range of small molecule API in the US
Regulatory
MoonLake Immunotherapeutics faces Securities Class Action after disastrous Phase III trial results
The announcement about the trial results for the product candidate sonelokimab, a highly anticipated treatment for patients with skin disease, saw MoonLake investors' shares fall by about 90%, prompting an investigation into whether or not they were misled